| Initial model | Final model | ||
---|---|---|---|---|
 | OR (95% CIs) | P-value | OR (95% CIs) | P-value |
Male gender | 1.04 (0.50-2.17) | 0.9 | Â | Â |
Age | 1.01 (0.98-1.05) | 0.4 | Â | Â |
DM | 0.78 (0.33-1.87) | 0.6 | Â | Â |
Smoking | 0.65 (0.31-1.36) | 0.2 | Â | Â |
CAD | 1.61 (0.75-3.45) | 0.2 | 1.80 (0.95-3.42) | 0.07 |
PAD | 1.71 (0.62-4.66) | 0.3 | Â | Â |
Cerebrovascular disease | 0.64 (0.17-2.35) | 0.5 | Â | Â |
Baseline LDL-C (mg/dl) | 0.98 (0.97-0.99) | 0.001 | 0.98 (0.97-0.99) | <0.001 |
Combined therapy with statin and ezetimibe | 1.92 (0.81-4.56) | 0.1 | Â | Â |
Very high potency LDL-C lowering regimen | 1.06 (0.36-3.10) | 0.9 | Â | Â |
Fenofibrate | 1.05 (0.34-3.42) | 0.9 | Â | Â |
n3 fatty acids | Â | Â | Â | Â |